Last reviewed · How we verify

Eugonia — Portfolio Competitive Intelligence Brief

Eugonia pipeline: 3 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

3 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
cetrorelix (cetrotide) cetrorelix (cetrotide) marketed GnRH antagonist GnRH receptor Reproductive/Fertility
uHCG 7500 IU uHCG 7500 IU marketed
Arvekap, Pregnyl Arvekap, Pregnyl marketed Gonadotropin; human chorionic gonadotropin (hCG) LH receptor (luteinizing hormone receptor) Reproductive/Fertility; Endocrinology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. AEterna Zentaris · 1 shared drug class
  2. Assaf-Harofeh Medical Center · 1 shared drug class
  3. EMD Serono · 1 shared drug class
  4. El Shatby University Hospital for Obstetrics and Gynecology · 1 shared drug class
  5. Instituto Valenciano de Infertilidad, IVI VALENCIA · 1 shared drug class
  6. Instituto de Investigacion Sanitaria La Fe · 1 shared drug class
  7. Jiangsu HengRui Medicine Co., Ltd. · 1 shared drug class
  8. Merck KGaA, Darmstadt, Germany · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Eugonia:

Cite this brief

Drug Landscape (2026). Eugonia — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/eugonia. Accessed 2026-05-14.

Related